Adtralza 150 mg solution for injection in pre-filled syringe
LP0162-1335
Phase 2 small_molecule active
Quick answer
Adtralza 150 mg solution for injection in pre-filled syringe for Treatment of moderate-to-severe Atopic dermatitis is a Phase 2 program (small_molecule) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LEO Pharma A/S
- Indication
- Treatment of moderate-to-severe Atopic dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active